Author:
Mastbergen Simon C.,Saris Daniël B. F.,Lafeber Floris P. J. G.
Publisher
Springer Science and Business Media LLC
Reference128 articles.
1. Report No. CPMP/EWP/784/97 (Committee for Proprietary Medicinal Products [CPMP], London, 1998).
2. FDA. Guidance for induistry: clinical development programs for drugs, devices and biological products intended for the treatment of OA. U.S. Food and Drug Administration [online] , (1999).
3. Mastbergen, S. C. & Lafeber, F. P. Animal models of osteoarthritis—why choose a larger model? US Musculoskeletal Review 4, 11–14 (2009).
4. Bingham, C. O. 3rd. et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum. 54, 3494–3507 (2006).
5. Bruyere, O. et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 16, 254–260 (2008).
Cited by
118 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献